MedTrace Logo

Glioblastoma Platelet Activation Study

NCT02887417 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2017-08-01

No results posted yet for this study

Summary

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Conditions

Sponsors & Collaborators

  • University Medicine Greifswald

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02887417 on ClinicalTrials.gov